ClinicalTrials.gg
CompletedNCT06790394CATIUpdated Oct 23, 2026

Test-retest Study With [18F]FBB in Cardiac Amyloidosis

A Phase 1 interventional study of Florbetaben F18 in Cardiac Amyloidosis, sponsored by Lantheus Germany GmbH. Completed at 2 sites in United Kingdom. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Lantheus Germany GmbH (part of Lantheus Holdings, Inc.) · Phase 1, Interventional, and Diagnostic

Updated Oct 23, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Amyloid Neuropathies, Familial with a site in United Kingdom — 5 open to participants now, 6 under way, 2 of them phase 3. Amyloid Neuropathies, Familial · United Kingdom.

Enrollment
17th of 18
15 · median 209
Started
2025
with 2 others
Phase 1
3 of 24
none open now
Registered
24th of 24
by date
Lead sponsor
2 of 24
Lantheus Germany GmbH

Among the 24 studies in Amyloid Neuropathies, Familial with a site in United Kingdom, this one is the 17th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2025, is one of 3 in phase 1, and was the 24th registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

5 of the 24 studies in Amyloid Neuropathies, Familial with a site in United Kingdom are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Amyloid Neuropathies, Familial with a site in United Kingdom, or all of them as a file.
02

Study summary

This study is an open-label study to evaluate and characterize test-retest reliability of [18F]florbetaben PET in subjects with AL-CA and ATTR-CA compared to non-CA subjects. Quantification of the [18F]florbetaben parameters related to the deposition of amyloid in the heart (such as Myocardial Tracer Retention (MTR) or Retention Index (RI)), and the variability in these parameters after repeated imaging will be evaluated. Measurement of blood metabolites and comparison of invasive with non-invasive quantification of [18F]florbetaben uptake in the heart will be performed.

03

Conditions studied

  • Cardiac Amyloidosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Inclusion criteria (for all subjects):

    • Males and females aged ≥40 years
    • Able to understand, sign, and date written
    • Written informed consent must be obtained before any assessment is performed
    • Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or for at least 1 year (no menses for 12 months without an alternative medical cause). If they are of , they must commit to use of a highly effective measure for one week after the PET scan (including combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner or sexual abstinence)
    • Male subjects and their partners of childbearing potential must commit to the use of a highly effective method of contraception for a minimum of 90 days following each PET scan (including, for female partners of childbearing potential, combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, male subjects with vasectomy or sexual abstinence)
    • Male subjects must commit to not donate sperm for a minimum of 90 days after the PET scan
    • Medications taken for treatment of multiple myeloma or chronic diseases of the heart or tafamides treatment are maintained on a stable dosage regimen.
    • Patients on stable coagulation, if arterial blood sampling isperformed.
  • Inclusion criteria for AL-CA and ATTR-CA patients:

    • Patients with a clinical diagnosis of cardiac AL amyloidosis or cardiac ATTR diagnosis according to diagnostic criteria
  • Inclusion criteria for control patients:

The control subjects must meet one of the following criteria:

  • Patients without heart failure and no suspicion of cardiac amyloidosis OR
  • Patients with impaired heart function but cardiac amyloidosis ruled out by echocardiography, CMR or cardiac OR
  • Patients with known plasma cell dyscrasia (MGUS, multiple myeloma) but no clinical signs of cardiac amyloidosis detected by echocardiography or CMR

Exclusion Criteria:

  • Subject has received, in the last 3 months, or currently receives amyloid targeting monoclonal antibody therapy.
  • Any known allergic reactions or towards any compound of the study drug
  • value \< 10 g/dL
  • Severe hepatic impairment ( or ALT >5 x ; >3 x ULN)
  • Subject receives hemodialysis or peritoneal dialysis
  • Inability to lay flat for up to 60 min
  • Pregnant, lactating or breastfeeding
  • Unwilling and/or unable to cooperate with study procedures
  • Having received a PET scan within one week before the 18F]florbetaben PET scan
  • For patients were arterial sampling isperformed: Subject has a to arterial cannulation, including but not limited to allergy to local anesthetics, peripheral vascular disease, Raynaud's phenomenon as determined by abnormal Allen's test or abnormal coagulation profile at screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Patients with cardiac disease

    All eligible AL, ATTR and non-CA patients will receive two injections of the investigational imaging agent florbetaben: at a baseline PET imaging session and at a follow-up PET imaging session to evaluate the test-retest imaging characteristics. 5 patients of each group will be required.

    Drug: Florbetaben F18

Interventions

  • Florbetaben F18 is a radioactive diagnostic agent being developed for the indication of PET imaging of the heart to detect amyloid pathology. All patients will receive two administrations of Florbetaben F18 at a radioactive dose of 300 megabecquerel (MBq).

06

What researchers measure

Primary outcomes

  1. Test-Retest variability of cardiac [18F]florbetaben PET uptake

    Percent Test-Retest variability (%) of cardiac 18F florbetaben PET

    Time frame: The duration of the study for participants may be up to 73 days.

Secondary outcomes

  1. Test-Retest variability of extracardiac [18F]florbetaben uptake

    Percent Test-Retest variability (%) of extracardiac 18F forbetaben PET

    Time frame: The duration of the study for participants may be up to 73 days.

  2. Net influx rate derived from full tracer kinetic modelling

    Net influx rate Ki \[ml/cm3/min\]

    Time frame: The duration of the study for participants may be up to 73 days.

  3. Volume of distribution derived from full tracer kinetic modelling

    Volume of distribution Vd

    Time frame: The duration of the study for participants may be up to 73 days.

  4. Safety and tolerability of [18F]florbetaben

    Number of participants with treatment-related adverse events as assessed by CTCAE version 5.0.

    Time frame: The duration of the study for participants may be up to 73 days.

07

Study locations

2 sites
  • Royal Free Hospital
    London, NW3 2QG, United Kingdom
  • King's College London
    London, SE1 7EH, United Kingdom
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2025 to primary completion in Oct 2026, 11 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Sep 2026 → Oct 2026 and completion Sep 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2024
First posted
Jan 24, 2025
StartActual
Oct 21, 2025
Primary completionActual
Oct 7, 2026was Sep 2026
CompletionActual
Oct 7, 2026was Sep 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 23, 2026
Primary completion
Sep 2026→Oct 7, 2026 (actual)
Oct 23, 2026
Study completion
Sep 2026→Oct 7, 2026 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Recruiting→Completed
    Primary completion Sep 2026→Oct 7, 2026 (now actual)
    Study completion Sep 2026→Oct 7, 2026 (now actual)
    + 4 other changes: identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06790394
Collaborators
pharmtrace
Responsible party
Sponsor
First posted
Jan 24, 2025
Start date
Oct 21, 2025
Primary completion
Oct 7, 2026
Completion
Oct 7, 2026
Last update
Oct 23, 2026

Study contacts

Andrew Stephens, MD, PhD
study director · Lantheus Germany GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Florbetaben f-18

Start the discussion